BioCentury
ARTICLE | Financial News

TCR2 seeks IPO as first program slated to enter clinic

December 28, 2018 10:56 PM UTC

Looking to bring at least one of its cell therapy programs to the clinic next year, TCR2 Therapeutics Inc. (Cambridge, Mass.) filed on Friday to raise $100 million in an IPO on NASDAQ.

TCR2 is developing T cell receptor fusion constructs (TRuCs), which comprise tumor antigen recognition domains fused to TCRs. The company thinks its TRuCs could have greater activity against solid tumors than CAR T therapies, and broader applicability than TCR therapies (see "TRuCs vs. CARs")...

BCIQ Company Profiles

TCR2 Therapeutics Inc.